Travelers over 60 advised to seek safer //vaccination alternatives . Individuals aged 60 and above are now being urged not to ...

In calling for more clinical testing of vaccines in younger people and those who face a low risk of severe disease from Covid ...

Adar Poonawalla, CEO, Serum Institute of India, on life after Covid, vaccine pricing, and expansion into new frontiers.

The EMA now advises against using the drug for people aged over 65 after 17 serious adverse effects were recorded in this age ...

The FDA and CDC are recommending a pause on the use of Ixchiq (chikungunya vaccine, live) in patients 60 years and older during an ongoing safety investigation.

Infectious disease stocks stumbled in the early months of 2025, with the BioWorld Infectious Disease Index (BIDI) plunging 17.83% by the end of April, well behind the broader markets. By comparison, ...

(Reuters) - The U.S. Centers for Disease Control and Prevention has accepted its advisory panel's recommendations on vaccines ...

The approval applies to anyone aged 18 and older who has a risk of being exposed to the virus. But the FDA and the Centers ...

US health officials are telling travelers aged 60 and older to avoid a chikungunya vaccine while they investigate possible side effects.

The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events. As of May 7, 17 serious events, including two deaths, have been reported ...

The FDA and the Centers for Disease Control and Prevention (CDC) have jointly recommended pausing the use of Valneva’s chikungunya vaccine Ixchiq in the United States amid ongoing investigations into ...

A study of bloodstream infections in Ontario finds attributable mortality due to AMR over 5 years was 896 deaths, or 1.2 per 100,000 population per year.